Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CLDIthis companyCalidi Biotherapeutics, Inc.	$0.72	-0.2×	1.34×	0×	-0.11×	1272.0%	0.0%	0.0%	0.0%	-529.6%	-314.4%	-425.4%	0.68×	0.17×	-97.78×	1.59×	0.0%	1	-36.44	2	C+
CNSPCNS Pharmaceuticals, Inc.	$3.97	-0.15×	0.51×	0×	0.29×	75.0%	0.0%	0.0%	0.0%	-350.5%	-329.5%	-594.1%	0.07×	0.43×	-1,049.68×	1.98×	0.0%	1	-7.36	2	C+
SILOSilo Pharma, Inc.	$1.53	-0.68×	0.45×	39.53×	0.45×	443.7%	-1128.9%	-5937.0%	-5863.5%	-67.0%	-61.5%	-163.6%	0×	1.14×	-114.76×	11.36×	0.0%	1	-6	2	C+
SNGXSoligenix, Inc.	$0.34	-0.63×	1.31×	0×	0.05×	251.4%	0.0%	0.0%	0.0%	-209.4%	-200.5%	-147.7%	0.07×	0.65×	0×	2.39×	0.0%	2	-34.78	3	B
SXTP60 Degrees Pharmaceuticals, Inc.	$0.57	-0.17×	0.39×	1.35×	-0×	-3717.1%	22.3%	-771.6%	-732.8%	-212.8%	-219.7%	-519.4%	0.04×	0.19×	-994.05×	2.66×	0.0%	2	-21.39	2	C+
XBIOXenetic Biosciences, Inc.	$1.91	-1.37×	0.5×	1.24×	1.56×	-1576.3%	100.0%	-95.2%	-90.1%	-36.2%	-38.3%	-61.9%	0×	2.94×	0×	8.32×	0.0%	3	-36.91	1	C-
Peer median	—	-0.63×	0.5×	1.24×	0.29×	75.0%	0.0%	-95.2%	-90.1%	-209.4%	-200.5%	-163.6%	0.04×	0.65×	-114.76×	2.66×	0.0%	2	-21.39	2	—